Immunovia AB is a diagnostic company that develops and markets high-precision blood tests for the early detection of cancer and autoimmune diseases, founded on Immunovia’s exclusive analysis platform called IMMray ™. The tests are based on biochip research of antibody biomarkers, learning complex devices, and bioinformatics to identify a set of applicable biomarkers involving a safe disease. Therefore, it forms an exclusive “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and cutting-edge studies in the Department of Immunotechnology at Lund University and the CREATE Health Cancer Center in Sweden.
The first product, IMMray ™ PanCan-d, is recently undergoing a clinical evaluation in some of the world’s largest clinical studies on pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is lately in the final validation phase for early sales in the fourth quarter of 2020. Once validated, IMMray ™ PanCan-d will be the first blood test for early diagnosis of pancreatic cancer on the market, with survival prospects and patient outcomes in particular.
Immunovia shares (IMMNOV) are indexed on Nasdaq Stockholm. For more information, visit www.immunovia.com.
For information, contact: Julie Silber Director of Investor Relations, Immunovia Email: [email protected] Tel: 46-7-93-486-277
This data is provided to you through Cision https://news.cision.com
https://news.cision.com/immunovia-ab/r/registration-details-for-immunovia-s-second-webinar-in-the-series-on-immray–pancan-d–commercial-te, c3183172
View content: https://www.prnewswire.com/news-releases/registration-details-for-immunovias-second-webinar-in-the-series-on-immray-pancan-d-commercial-test-model-study – update-activities-launch-301120222.html
SOURCE Immunovia AB